FDA Approves Kite Pharma’s Cancer Drug Yescarta

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

FDA Approves Kite Pharma’s Cancer Drug Yescarta
Photo by Drew Hays on Unsplash

Santa Monica-based Kite Pharma, a subsidiary of biopharma giant Gilead Sciences, announced on Friday that it has received approval from the Food and Drug Administration for a new immunotherapy drug that can be used in the early-stage treatment of certain cancers.


Yescarta, an intravenous CAR-T cell treatment that aims to bolster the immune system to fight cancer cells, is the first therapeutic of its kind to receive FDA approval for the early treatment of large B-cell lymphoma—a type of non-Hodgkin lymphoma—that has either relapsed or can’t be addressed with other cancer treatments like chemoimmunotherapy.

Most CAR-T cell therapies are reserved as a last resort for cancer patients who have exhausted all other options. At that point, however, their immune systems may be too weak to effectively utilize the therapeutic. While most clinical CAR-T cell trials involve patients who are at an advanced stage in their cancer treatments, Yescarta’s clinical trial was filled with patients who used the drug as a second- or third-resort.

CAR-T cell therapies have taken the oncology world by storm as a promising, potentially less invasive route for treating cancers, with many local biotech firms making moves in the space. In January, West Hills-based ImmPACT Bio raised $111 million to further its work of reengineering patients’ cells to boost the immune system. Culver City-based Appia Bio, meanwhile, emerged from stealth last spring to create off-the-shelf cell therapies that can be delivered quicker and cheaper to patients, and inked a deal with Kite Pharma last August to develop CAR-T cell treatments.

Kite Pharma has focused almost exclusively on CAR-T cell therapies since it was founded in 2009. Gilead Sciences acquired Kite for $11.9 billion in 2017.

“Kite started with a very bold goal: creating the hope of survival through cell therapy,” Kite CEO Christi Shaw said in a statement. “Today’s FDA approval brings that hope to more patients by enabling the power of CAR-T cell therapy to be used earlier in the treatment journey. This milestone has been years in the making.”

https://twitter.com/KeerthiVedantam
keerthi@dot.la

Subscribe to our newsletter to catch every headline.

Cadence

LA Venture: Taylor Adams on His ‘Blended Approach’ to VC

Minnie Ingersoll
Minnie Ingersoll is a partner at TenOneTen and host of the LA Venture podcast. Prior to TenOneTen, Minnie was the COO and co-founder of $100M+ Shift.com, an online marketplace for used cars. Minnie started her career as an early product manager at Google. Minnie studied Computer Science at Stanford and has an MBA from HBS. She recently moved back to L.A. after 20+ years in the Bay Area and is excited to be a part of the growing tech ecosystem of Southern California. In her space time, Minnie surfs baby waves and raises baby people.
LA Venture: Taylor Adams on His ‘Blended Approach’ to VC
Taylor Adams

On this episode of the LA Venture podcast, Los Angeles native Taylor Adams talks about how his philanthropic work and time in venture capital motivated him to build Rise Together Ventures, a Santa Barbara-based venture franchise combining venture funding with philanthropy.

Read more Show less

Mullen Automotive Increases Authorized Common Stock From 1.75 Billion Shares to 5 Billion

David Shultz

David Shultz reports on clean technology and electric vehicles, among other industries, for dot.LA. His writing has appeared in The Atlantic, Outside, Nautilus and many other publications.

Mullen Automotive Increases Authorized Common Stock From 1.75 Billion Shares to 5 Billion
Photo by Ringo Chiu/ Shutterstock

In a virtual stockholder meeting today, EV hopeful Mullen Automotive announced that shareholders had approved a proposal to increase authorized common stock from 1.75 billion total shares up to 5 billion total shares.

Read more Show less

Statevolt Brings the U.S. One Step Closer to Producing Batteries on the Shores of the Salton Sea

David Shultz

David Shultz reports on clean technology and electric vehicles, among other industries, for dot.LA. His writing has appeared in The Atlantic, Outside, Nautilus and many other publications.

Statevolt Brings the U.S. One Step Closer to Producing Batteries on the Shores of the Salton Sea

Statevolt, a battery cell manufacturing company, has secured a site for their gigafactory in the Imperial Valley. As the American sister to their Italian counterpart, Italvolt, the company is seeking to rapidly expand its battery production facilities to the United States by capturing funding created by the Inflation Reduction Act.

Read more Show less
RELATEDEDITOR'S PICKS
LA TECH JOBS
interchangeLA
Trending